Léa Caplan
A5059959437- Inflammatory Bowel Disease
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Eosinophilic Esophagitis
- Intramuscular injections and effects
- Dermatological and COVID-19 studies
- Vaccine Coverage and Hesitancy
- Tuberculosis Research and Epidemiology
- vaccines and immunoinformatics approaches
- Peripheral Neuropathies and Disorders
- Immunotherapy and Immune Responses
- Drug-Induced Adverse Reactions
- Liver Disease Diagnosis and Treatment
- COVID-19 Impact on Reproduction
- Machine Learning in Healthcare
- Heparin-Induced Thrombocytopenia and Thrombosis
- Diabetes and associated disorders
- COVID-19 and healthcare impacts
- Urticaria and Related Conditions
- COVID-19 and Mental Health
- Health Systems, Economic Evaluations, Quality of Life
- Hematological disorders and diagnostics
- Urban Transport and Accessibility
University of Calgary
2022-2024
Institute for Community Health
2023
Abstract BACKGROUND Rising incidence and prevalence of inflammatory bowel disease (IBD) observed historically in early-industrialized regions now also appear newly-industrialized emerging regions. The epidemiology IBD has been proposed to progress across epidemiologic stages: 1. Emergence (low prevalence); 2. Acceleration Incidence (rapid rising incidence); 3. Compounding Prevalence (stabilizing incidence, rapid prevalence). AIM To gather real-world data on the characterize global each stage...
INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), risk IBD flare. METHODS: Individuals were interviewed for to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association antibody titers ISR. RESULTS: Severe occurred 0.03%. ISR significantly associated levels fourth dose (geometric...
Background Individuals with inflammatory bowel disease (IBD) who are immunocompromised may have a reduced serological response to the SARS-CoV-2 vaccine. We investigated responses following 1 st , 2 nd and 3 rd doses of vaccination in those IBD. Methods A prospective cohort study persons IBD ( n = 496) assessed 1–8 weeks after dose vaccination, dose, 8 or more at least week dose. Seroconversion geometric mean titer (GMT) 95% confidence intervals (CI) were for antibodies spike protein....
Abstract During the 20th century, inflammatory bowel disease (IBD) was considered a of early-industrialized regions in North America, Europe, and Oceania. At turn 21st incidence IBD increased newly-industrialized emerging Africa, Asia, Latin while prevalence started to grow steadily. Changes denote evolution across four epidemiologic stages: Stage 1 (Emergence), characterized by low prevalence; stage 2 (Acceleration Incidence), rapidly rising 3 (Compounding Prevalence), decelerating,...
Abstract BACKGROUND SARS-CoV-2 vaccine response may be reduced in seniors (age 65+) with inflammatory bowel disease (IBD) and those on anti-TNF therapy. A challenge of the COVID-19 era has been conveying rapid-evolving health information, especially for groups higher risk poor outcomes such as immunocompromised individuals. AIM To develop sharable, interactive 3D models relationship age days from dose serological responses to vaccines people IBD who are either or not METHODS prospective...
Abstract BACKGROUND Epidemiologic stages of inflammatory bowel disease (IBD) have been proposed: 1. Emergence (low incidence and prevalence); 2. Acceleration in Incidence (rapidly rising incidence, low 3. Compounding Prevalence (stabilizing rapidly prevalence). To date, these theoretical without quantified definitions prevalence. AIM use machine learning to determine prevalence ranges corresponding the epidemiologic provide stage classifications across time for global regions. METHODS We...
Abstract BACKGROUND A theoretical framework for population-level transition across four epidemiologic stages has been proposed inflammatory bowel disease (IBD): 1. Emergence (low incidence/prevalence); 2. Acceleration in Incidence (rapid rising incidence); 3. Compounding Prevalence (stabilizing incidence, rapid prevalence); and 4. Equilibrium (decelerated prevalence), which no region entered yet. Many regions of the early-industrialized world (North America, Europe, Oceania) are currently...
Introduction: The rapid development and distribution of SARS-CoV-2 vaccines has raised concerns surrounding vaccine safety in immunocompromised populations, such as those with inflammatory bowel disease (IBD). We described adverse events (AEs) following vaccination IBD to determine any relationship AEs post-vaccination antibody titres. Methods: Individuals from a prospective cohort Calgary, Canada who received first, second, third, and/or fourth dose (Pfizer-BioNTech, Moderna, AstraZeneca)...
Injuries resulting from collisions between a bicyclist and driver are preventable have high economic, personal societal costs. Studying the language choices used by police officers to describe factors responsible for child bicyclist-motor vehicle may help shift prevention efforts away vulnerable road users motorists environment. The overall aim was investigate how attribute blame in (≤18 years) bicycle-motor collision scenarios.A document analysis approach analyse Alberta Transportation...
Introduction: Vaccines have been shown effective regardless of Body Mass Index (BMI), obesity may impact antibody levels compared to healthy weight subjects. The durability vaccine response in people with has not definitively studied those IBD. This study aims determine the association between elevated BMI and serological responses (SR) SARS-CoV-2 vaccination individuals Methods: vaccinated (≥ 2 doses) adults IBD were recruited from STOP COVID-19 cohort. Patient height recorded at...
Introduction: Smoking (SMK) has been associated with reduced IgG antibody responses to two-dose regimens of SARS-COV-2 immunization in the general population1. The impact SMK on serological (SR) additional SARS-CoV-2 doses is lacking within IBD population. We aim describe status and SR (>2) vaccination a cohort patients. Methods: Patients were recruited from vaccinated adults diagnosis (STOP COVID-19 IBD)2, all had minimum two vaccine. was documented at recruitment; individuals stratified...
Introduction: Anti-tumor necrosis factor (TNF) reduces the serological responses (SR) to SARS-CoV-2 vaccination and impairs SR durability within individuals with IBD.1-3 Additional doses of effectively increase antibody titers in patients treated anti-TNF agents, are still lower compared healthy controls.4 5 Data comparing between monotherapy combination therapy lacking. This study aims compare from IBD or combined an immunomodulator. Methods: Adults IBD, at least two a vaccine, (anti-TNF...
Abstract Background Adequate serological responses following two-dose regimens and additional doses of SARS-CoV-2 vaccination have been demonstrated for the vast majority those with IBD. However, antibody levels 2nd, 3rd, 4th dose may decrease over time in IBD population. Purpose We assessed durability to a cohort patients. Method Adults who received at least one vaccine (n=559) were evaluated response spike protein using Abbott IgG II Quant assay seroconversion threshold ≥ 50 AU/mL. The...